Phase II trial demonstrates everolimus improves outcomes in metastatic gastroenteropancreatic neoplasms, suggesting effective treatment strategy.
The MAVERIC trial demonstrated encouraging clinical benefit of everolimus in metastatic GEP-NEN and LCNEC (Ki-67 20%-55%) following first-line CT. Toxicity was consistent with the known safety profile of everolimus. This strategy was particularly effective in GEP-NEN patients and warrants further investigation.
No takes yet. Share an insight, caveat, or question.
Antonuzzo et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: